Back to top
more

Nivalis Therapeutics, Inc. (ALPN)

(Delayed Data from NSDQ)

$6.24 USD

6.24
7,474

-0.08 (-1.27%)

Updated May 3, 2019 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[ALPN]

Reports for Purchase

Showing records 21 - 40 ( 156 total )

Industry: Medical - Drugs

Record: 21

12/01/2023

Industry Report

Pages: 19

The Wedbush Monthly Check-Up: December 2023

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 22

11/21/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for ALPN 112123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 23

11/15/2023

Daily Note

Pages: 6

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 24

11/15/2023

Company Report

Pages: 7

3Q23 Results; Building on Recent Clinical Momentum

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 25

11/15/2023

Company Report

Pages: 6

Q3 Financials; RUBY-3 Data at ASN Impressive, Ph3 Planned for 2H:24

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 26

11/05/2023

Industry Report

Pages: 13

The IgAN Era Continues, While Xphozah Makes A Splash Ahead Of Launch

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 27

11/03/2023

Daily Note

Pages: 24

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 35.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 28

11/03/2023

Company Report

Pages: 7

RUBY-3 Continues to Shine; Povetacicept Exhibits Initial Efficacy in IgAN

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 29

11/03/2023

Daily Note

Pages: 6

Dual AANEM ''23 Presentations Give Povetacicept More Polish

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 30

11/02/2023

Company Report

Pages: 8

IgAN See Best in Class Potential; Ph 3 Planned for 2H24; Broad Development Open

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 31

10/16/2023

Industry Report

Pages: 7

Kidney Week 2023 - Gearing Up For What''s New in Glomerular Disease

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 32

09/13/2023

Company Report

Pages: 9

Povetacicept Finds a Potential New Target in Myasthenia Gravis

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 33

08/31/2023

Company Report

Pages: 7

RUBY-3 Begins to Sparkle With Favorable SMC Review and Enrollment Initiation in Second IgAN Cohort

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 34

08/31/2023

Daily Note

Pages: 4

RUBY-3 IgAN Cohort Progresses; Early Data Ahead at ASN

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 35

08/15/2023

Company Report

Pages: 7

2Q23 Results; Steady Progress for RUBY Studies; Price Target Upped to $17

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 36

08/15/2023

Company Report

Pages: 6

Q2 Financials; Initial RUBY-3 Data Ahead at ASN

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 37

08/15/2023

Daily Note

Pages: 8

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 38

05/12/2023

Company Report

Pages: 6

Q1 Financials; RUBY-3 Initiated, RUBY-1 Updated Data at EULAR

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 39

05/12/2023

Company Report

Pages: 7

1Q23 Results; RUBY Studies Continue to Progress; Preliminary Data By YE23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 40

05/09/2023

Industry Report

Pages: 7

The Renal Renaissance - Key Highlights From Wedbush Event

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 12.50

Research Provided by a Third Party
// eof